Landscape of chromatin control element patents: Positioning effects in pharmaceutical bioproduction

Nature Biotechnology

Volumn 29, Issue 7, 2011, Pages 593-597

  Palazzoli, Fabien ^a   Bire, Solenne ^a   Bigot, Yves ^a   Bonnin Rouleux, Florence ^a  

^a UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLOBIN; BETA INTERFERON; DNA; HYBRID PROTEIN; OVALBUMIN; RECOMBINANT PROTEIN;

ARTICLE; CELL THERAPY; CHROMATIN; CHROMATIN CONTROL ELEMENT; CHROMATIN STRUCTURE; DNA RESPONSIVE ELEMENT; DNA SEQUENCE; DNA SYNTHESIS; DRUG COST; DRUG MANUFACTURE; EUCHROMATIN; GENE CASSETTE; GENE EXPRESSION; GENE SEQUENCE; GENE SILENCING; GENE THERAPY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETIC VARIABILITY; GOVERNMENT; HETEROCHROMATIN; HUMAN; MATRIX ATTACHMENT REGION; NONHUMAN; PATENT; PHARMACEUTICAL CARE; PHARMACEUTICS; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REGULATOR GENE; TRANSGENE; UBIQUITOUSLY ACTING CHROMATIN OPENING ELEMENT;

CHROMATIN; GENE TRANSFER TECHNIQUES; GENETIC ENHANCEMENT; PATENTS AS TOPIC; TECHNOLOGY, PHARMACEUTICAL; UNITED STATES;

EID: 79960206845     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1907     Document Type: Article

References (11)

1. Chen, W.Y. et al. Proc. Natl. Acad. Sci. USA 94, 5798-5803 (1997).
2. Harraghy, N. et al. Curr. Gene Ther. 8, 353-366 (2008).
3. Kwaks, T. & Otte, A. Trends Biotechnol. 24, 137-142 (2006).
4. Benton, T. et al. Cytotechnology 38, 43-46 (2002).
5. Williams, S. et al. BMC Biotechnol. 5, 17 (2005).
6. Kwaks, T.H. Nat. Biotechnol. 21, 553-558 (2003).
7. van Blokland, H.J. et al. J. Biotechnol. 128, 237-245 (2007).
8. Girod, P.A. et al. Nat. Methods 4, 747-753 (2007).
9. Buceta, M. et al. Gene Ther. 18, 7-13 (2010).
10. Ledergerber, W. & Kurt, A. World Pat. Inf. 25, 57-62 (2003).
11. Williams, S. & Cranenburgh, R. Innov. Pharm. Technol. 26, 52-56 (2008).